• Newsroom
  • Join us!
  • Newsletter
  • Kontakt
  • English English English en
  • Deutsch Deutsch German de
Experts Institut
  • Business Consulting
    • Business Solutions
      • Digitization
      • Sustainability Corporate strategy
      • Management systems
      • Project management
      • Strategy & Performance
      • Transformation & Leadership
  • GXP Consulting
    • GMP Beratung
      • Audits & inspections
      • GMP/GXP training courses
      • GMP Aircheck4
      • Continuous Manufacturing
  • Industries
    • Pharma
    • Service providers & trade
    • Automotive
    • FOOD & BEVERAGES
    • Financial service providers & insurances
    • Informationstechnik (IT)
    • Aerospace
  • Academy
    • Individuelle Inhouse-Schulungen
      • GMP/GXP training courses
    • Experts Institut Events
      • Academy
    • Direkt buchen
      • Live-Events
      • On-Demand Webinar
  • Kunden
  • Über uns
    • Über uns
      • Guideline
      • Portrait
      • Team
      • Geschäftsführung
      • Vision
      • Events
      • History Experts Institute
      • Sustainability at the Experts Institute
      • Social responsibility
    • Wissen
      • GMP Glossary
      • FAQ – Frequently asked questions in the GMP environment
      • Videos
    • Blog
      • Newsroom
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
  • Link to LinkedIn
  • Link to Xing

Tag Archive for: Germ count monitoring

GMP

The new ANNEX 1 02/2020

ESSAY No. 1 – Acceptance criteria for germ count monitoring in cleanrooms

One of the significant revisions in the draft of the new Annex 1 is the change in the limitation of the bacterial count in cleanroom class “A”. Whereas the previous requirement was that a maximum value of “< 1” was permitted in the core zone of aseptic production, the limit is now set to “no growth”, i.e. “0” CFU/sampling.

Sampling point

This will be a challenge in the future because, in contrast to the new requirement, the current value is an average value per sampling point (air bacteria count, sedimentation plate, contact plate)1) , which means that the number of 1 bacteria can theoretically be exceeded in a sample. According to general GMP understanding, the new requirement implies that the occurrence of a germ immediately leads to an investigation as part of the company’s own deviation management, whereby the cause of the origin of the germ should be found with the greatest possible probability.

Requirement in the new Annex 1

If the requirement in the new Annex 1 is included in the ongoing discussion that in future it should be possible to fully monitor the cleanroom from outside, i.e. outside the A/B zone (suitable windows or camera systems are specifically recommended), this presents a new challenge. In FDA inspections, for example, it is already expected that monitoring activities (quality oversight) will be specifically incorporated into the evaluation of microbial findings in order to establish the greatest possible correlation between the sample train carried out and the event that took place.

For the pharmaceutical manufacturer

In the interpretation of the new Annex 1, this means for the pharmaceutical manufacturer: establishment of documented monitoring of the cleanroom with chronological allocation of sampling/monitoring and events that actually took place in the cleanroom. An exciting task!

Source: 1) ZLG Aide memoire “Monitoring of sterile manufacturers”

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

18. February 2023/0 Comments/by Dipl. Ing. Wolfgang Rudloff
https://experts-institut.com/wp-content/uploads/2023/02/Untitled-design-5.jpg 800 800 Dipl. Ing. Wolfgang Rudloff https://experts-institut.de/wp-content/uploads/2023/02/GEMI_Logo_Slogan_color_RGB.webp Dipl. Ing. Wolfgang Rudloff2023-02-18 17:13:092024-10-29 07:59:21The new ANNEX 1 02/2020
Recent
  • AI
    Pharmaceutical-grade use of generative AI: regulations,...2 weeks 
  • CSRD
    CSRD in the omnibus procedure: Basics, terms and what companies...4 weeks 
  • KI in der Pharmaindustrie: Annex 22 & EU AI Act
    AI in the pharmaceutical industry: Annex 22 & EU AI...1 month 
  • GMP
    The most important GMP findings for 2025 and forecasts for...15. December 2025 - 15:52
Popular
  • Deviation Management
    Enhancing Process Stability through Effective Deviation...27. March 2025 - 11:07
  • Supplier-Audit Reports
    Untrue Supplier-Audit-Reports: The Danger of Ethnocentric...9. January 2025 - 11:29
  • Qualitätssicherungsvereinbarungen
    Insights into our project experience: Successful implementation...4. December 2024 - 8:59
  • Cannabis
    GMP standards for medicinal cannabis: guaranteeing quality...19. November 2024 - 16:04

Tags

AI AI Annex Annex 11 Annex 22 Artificial Intelligence Audit audits Business Continuity Management Cannabis Certification Clean room Computerized systems Continuous Manufacturing CRA Cultures Cytostatics Data Integrity DORA Draft EU AI Act Germ count Germ count monitoring GMP GXP Health insurance Information security inspections ISMS ISO/IEC 42001 ISO 9001 ISO 27001 ISO standard Laboratory Machine Learning NIS-2 NIS2 Pharmacy QMS Quality management system Reagents Regulations Retaxation Sustainability Transformation

Kategorien

  • AI
  • Business Solutions
  • GMP
  • GXP
  • News
  • Retaxation
  • Sustainability
  • Uncategorized

Archiv

  • February 2026 (1)
  • January 2026 (2)
  • December 2025 (1)
  • November 2025 (1)
  • October 2025 (1)
  • September 2025 (1)
  • July 2025 (2)
  • March 2025 (1)
  • January 2025 (1)
  • December 2024 (1)
  • November 2024 (1)
  • October 2024 (3)
  • September 2024 (2)
  • August 2024 (2)
  • July 2024 (2)
  • May 2024 (1)
  • April 2024 (2)
  • March 2024 (2)
  • February 2023 (10)

Webpräsenz der Allianz für Cyber- Sicherheit
kununu widget

Business Solutions

  • Digitization
  • Sustainability
  • Management systems
  • Project management
  • Strategy & Performance
  • Transformation & Leadership

GMP / GXP Consulting

  • GMP Consulting
  • GMP audits & inspections
  • GMP/GDP training courses
  • GMP/pharmaceutical engineering
  • Continuous Manufacturing

EI Academy

  • GMP / GxP
  • Academy
  • Live events
  • On-demand webinar

New town

Experts Institut Beratungs GmbH
Weinstraße 85

D-67434 Neustadt a. d. Weinstraße

Phone: +49 (0)6321 969210
E-mail: info@expertsinstitut.de

Fax: +49 (0)6321 9692199

Bamberg

Experts Institut Beratungs GmbH
Untere Sandstraße 53

D-96047 Bamberg

Phone: +49 (0)951 51939330
E-mail: info@expertsinstitut.de

St. Gilgen (Austria)

Experts Institut Beratungs GmbH
Helenenstraße 16

A-5340 St. Gilgen, Austria

Tel.: +43 (0)6227 21068
E-Mail: info@expertsinstitut.de

  • Link to LinkedIn
  • Link to Xing

© 2024 Experts Institut Beratungs GmbH
  • Imprint
  • Data protection
  • AGBs
  • Cookie Directive (EU)
Scroll to top Scroll to top Scroll to top